BIO Asia–Taiwan 2023 亞洲生技大會

BIO Asia–Taiwan 2023 亞洲生技大會

≡

論壇議程總覽

2024 Innovation Forum Agenda

​​

2024 Innovation Forum Agenda

Date July 24-26, 2024

Venue July 24 Room 701C, 7F, TaiNEX2
July 25-26 Room 401, 4F, TaiNEX1

Day 1 - Wednesday, July 24
Day 2 - Thursday, July 25
Day 3 - Friday, July 26

09:00 – 10:15

Session 1 (Plenary) – Global Biotech Development

TBD
09:00 – 09:05

Conference Opening

Welcoming Remarks

Johnsee Lee, Chairman of BIO Asia–Taiwan 2024
Chung-Hsiun Wu, Chairman, Taiwan Bio Industry Organization
John F. Crowley, President and CEO, Biotechnology Innovation Organization (BIO)

09:05 – 09:15

Session Chair

Chung-Hsiun Wu, Chairman, Taiwan Bio Industry Organization

Industry Policy Lecture
​Impact of Key Policy and Regulatory Changing on Biopharma Industry

Hilary Stiss, Senior Manager, International Affairs, Biotechnology Innovation Organization (BIO)

09:15– 09:45

Industry Leader Lecture
Pioneering company creation model and opportunities in APAC

André Andonian, Chair of Flagship Asia Pacific, Flagship Pioneering
Sabrina Yusang Yang, Flagship Principal, Cofounder and Chief Innovation Officer of Empress Tx

09:45 – 10:15

Tang Prize Lecture

Exploration of Biological Diversity

Feng Zhang, Tang Prize Laureate; James and Patricia Poitras Professor, MIT, Core Member, Broad Institute of MIT and Harvard

10:20 – 12:05

Session 2 (Plenary) – Global Biotech Development

Welcome to the conference component of BIO Asia–Taiwan 2024, beginning with two Plenary
Sessions on Global Biotech Development. Hear from representatives of the Biotechnology
Innovation Organization (BIO), discussing biopharma policy and regulatory changes; and US-
based Flagship Pioneering, examining innovative company creation models as well as
collaboration opportunities within Asia. And don’t miss the Tang Prize Lecture; an Exploration of
Biological Diversity, by Feng Zhang, Tang Prize Laureate. In Session 2 we'll dive right into AI in
healthcare, funding and investment strategies, and emerging trends in both the pharmaceutical
industry and in the broader healthcare spaces. Join our esteemed lineup of speakers from Asia
and around the world as they offer their insights on navigating the global biotech landscape.

10:20 – 10:40

Global Biotech Top Trends --- From a US Silicon Valley VC Prospective

Anis Uzzaman, Founder & CEO, Pegasus Tech Ventures, Inc.

10:40 – 11:00

Bioconvergence: how the intersection of biology and technology can advance human health

Paru Deshpande, Vice President, Life Science Technologies, Imec vzw

11:100 – 11:20

Emerging Trends in the Global Health Industry

Zubin J. Daruwalla, M. D., PwC Singapore and Asia Pacific Health Industries Leader, PwC Singapore

11:20 – 11:40

Global trends and future opportunities in pharma

Brian Mi, President, Asia Pacific IQVIA​

11:40 – 12:00

Evidence based Cell and Gene Therapies: Global development for local benefit

Miguel Forte, President/ Chair, Board of Directors, International Society of Cell and Gene Therapy (ISCT); CEO/Co-Founder, Kiji Therapeutics

12:00 – 12:05

Closing Remarks

Chung-Hsiun Wu, Chairman, Taiwan Bio Industry Organization

12:30 – 14:00

Session 3 – Through International Alignment for a Healthier Taiwan

TBD
12:30 – 12:40

Opening Remarks

Chin-Ching Liu, Minister, National Development Council (Inviting)
Johnsee Lee, Chairman of BIO Asia–Taiwan 2024 (Inviting)
Hidehito Katsuma, President of IRPMA

12:40 – 12:55

Empowering Taiwanese Biomedical Startups through International Collaboration

Lilly Wong, Partner/Managing Director at PwC Financial Advisory Services

12:55 – 13:10

Establish an Interdisciplinary Collaboration Platform for Biomedical Innovations in Taiwan

Eric Y. Chuang, General Director, Biomedical Technology and Device Research Laboratories (BDL), ITRI

13:10 – 13:25

Toward Enhancing Japan's Drug Discovery Capabilities

​Toshihiko Takeda, Boston Consulting Group Senior Advisor, Former Ministry of Health, Labour and Welfare Medical Policy Bureau Director University of Tokyo graduate

13:25 – 13:55

Panel Discussion

Moderator:
Johnsee Lee, Chairman of BIO Asia–Taiwan 2024 (Inviting)

Panelists:

  • Toshihiko Takeda, Boston Consulting Group Senior Advisor, Former Ministry of Health, Labour and Welfare Medical Policy Bureau Director University of Tokyo graduate
  • Lilly Wong, Partner/Managing Director at PwC Financial Advisory Services
  • Eric Y. Chuang, General Director, Biomedical Technology and Device Research Laboratories (BDL), ITRI Frances Milnes, Standing Director of IRPMA
  • Frances Milnes, Standing Director of IRPMA
13:55 – 14:00

Closing Remarks

Hidehito Katsuma, President of IRPMA

14:10 – 15:40

Session 4 – ADC Drug development and manufacturing trends challenges and solutions

Antibody-Drug Conjugate (ADC) drugs, while becoming more and more mainstream, still
provide significant manufacturing challenges. This session will examine the latest ADC
development and manufacturing trends such as biomarker-incorporated ADCs, novel payloads,
site-specific conjugation, and novel combination therapies; identify challenges including payload
stability and manufacturing scalability; and consider solutions such as better process
optimization and improved conjugation technologies. Don't miss this deep dive into the world of
ADCs, led by some of the world's leading experts in this field.
14:10 – 14:15

Opening Remarks

Lee-Cheng Liu, Founder, Chairman & President, EirGenix, Inc.

14:15 – 14:35

Challenges and Opportunities of ADC Drug Development: Regulatory Considerations

Heidi Wang, CEO, OBI Pharma

14:35 – 14:55

Strategies for widening the therapeutic window

Gur Roshwalb, Partner, aMoon Fund

14:55 – 15:15

Nab2-ADC: Revolutionizing Antibody-Drug Conjugates with Enhanced Targeting and Safety

Gui-Dong Zhu, CEO, SparX Biopharmaceutical Corp.
15:15– 15:40

Panel Discussion

Moderator:
Lee-Cheng Liu, Founder, Chairman & President, EirGenix, Inc.

Panelists:

16:00 – 17:30

Session 5 – Frontier of Gene and Cell Therapies

This session will explore the latest advancements, challenges, and future developments in the
field of gene and cell therapies. Bringing together leading experts, researchers, and clinicians,
we'll provide a comprehensive overview of cutting-edge technologies, such as CRISPR gene
editing, CRT-T and stem cell therapy. We'll highlight current gene and cell therapy applications
as well as the new treatments on the horizon. We'll uncover both drivers and bottlenecks to
progress in this exciting discipline, including challenges from a regulatory, manufacturing, and
ethical perspective. Attendees can expect an invigorating discussion around this rapidly-
evolving topic.
16:00 – 16:03

Opening Remarks

Chien-Tsun Kuan, Ph.D, President / CEO and co-founder, ARCE Therapeutics, Inc.

16:03 – 16:20

Overview of Landscape for Cell and Gene Therapies; An update

John Tsai,Executive Partner, Syncona Ltd.

16:20 – 16:40

Driving the next generation of innovative and affordable cell therapies across indications

Alex Shih-Min Huang, Ph.D., VP and Head of Cell Therapy, BeiGene

16:40 – 16:55

Early Engagement Strategies to Cell and Gene Therapies Up for Success

Chia-Hua Maggie Ho, COO, Amarex Taiwan, LLC. 

16:55 – 17:10

Integration of MSC Value Chain with Enabling Manufacturing Platforms

David Chang, Ph.D., CEO, Taiwan Bio-Manufacturing Corporation (TBMC)

17:10 – 17:25

Investors viewpoint on cell and gene therapy

Gur Roshwalb, Partner, aMoon Fund

17:25 – 17:30

Closing Remarks

09:00 – 10:30

Session 6 – mRNA and New Therapeutic Modalities

This session delves into the transformative potential of mRNA technology in modern
therapeutics. From the pioneering application of mRNA in COVID-19 vaccines, our expert
speakers will highlight advancements in mRNA therapeutics beyond vaccines, including as
personalized cancer treatments, where mRNA can direct the immune system to target and
destroy cancer cells. Additionally, we'll cover the development of mRNA-based therapies for
genetic disorders, such as cystic fibrosis, where mRNA can be used to produce functional
proteins. The latest research on mRNA delivery systems, stability, and manufacturing will also
be covered, addressing the key challenges and future prospects of this promising technology.
Join us to learn how mRNA is revolutionizing the landscape of therapeutic modalities and
paving the way for innovative treatments.
09:00 – 09:05

Opening Remarks

Han-Chung Wu, Director , Academia Sinica(Biomedical Translation Research Center)

09:05 – 09:25

New Therapeutic Modalities for Treatment of Human Diseases

Yusuke Nakamura, President, National Institutes of Biomedical Innovation, Health and Nutrition

09:25 – 09:45

Updates for Gene Therapies - an industry perspective

John Tsai, Executive Partner, Syncona Ltd.

09:45 – 10:05

Initiated from Unthinkable with the Optimization (TBD)

Eric Huang, Former GM and CSO, Moderna Genomics

10:05 – 10:25

CMC Strategy for mRNA-LNP Vaccines and Therapeutics

Kelvin Chan, Director, Commercial Strategy & Business Development, Kudo Biotechnology, Inc.

10:25 – 10:30

Closing Remarks

Han-Chung Wu, Director , Academia Sinica(Biomedical Translation Research Center)

10:35 – 12:15

Session 7 – Taiwan BIO Awards-Successful Stories

TBD

12:25-13:55

Session 8 –Strategic Insights into CMC Program Design: Pioneering Biologics Development Excellence

This will be a deep-dive into Chemistry, Manufacturing, and Controls (CMC) program design, an
essential element of every biologics development facility. We'll explore the latest advancements
and best practices in CMC to ensure the quality, efficacy, and safety of biologics products.
Emphasis will be on developments and practices emerging in Asia, where robust CMC
strategies have accelerated the growth of the region's biopharmaceutical sector. Case studies
will highlight successful CMC frameworks, showcasing advancements in manufacturing
technologies, regulatory harmonization, and cross-border collaborations. Join us to understand
how strategic CMC program design is driving biologics excellence and contributing to the global
success of the biopharmaceutical industry.
12:25 – 12:30

Opening Remarks

Bobby Sheng, Chairman & CEO, Bora Biologics Co., Ltd.

12:30 – 12:45

Decoding CMC Program Design: Unveiling the Blueprint for Success in Biologics Development

Friedmund Bachmann, VP CMC, OncoOne Research & Development GmbH

12:45 – 13:00

TBD

Ignacio Asial, Founder and CEO, DotBio

13:00 – 13:15

Drug Bundle-Based ADC Platform: Achieving Site-Specific Conjugation, DAR of 8 or 12, and Dual Payloads

Hsing-Mao Chu, CEO, T-E Meds, Inc.

13:15 – 13:30

Innovative CMC and Manufacturing Technologies for Next-Generation Bioconjugate Drug Development

Paul Song, CSO, GeneQuantum Healthcare

13:30 – 13:45

Trends in CMC design for drug products: What works and what doesn’t

Alan Chang, CEO, Taron Solutions Limited

13:45 – 13:55

Closing 

13:30 – 14:30

Session 9 – Opening Ceremony

TBD

16:00 – 17:30

Session 10 – Translational Medicine, A Journey from Novelty to Commercial Success

This session explores the dynamic field of translational medicine, highlighting its journey
from innovative research to commercial triumph. Delve into the critical elements and processes
that bridge the gap between laboratory discoveries and marketable therapies. Case studies of
recent breakthroughs will illustrate how novel scientific insights are transformed into commercially
viable treatments, addressing unmet medical needs. Topics will include strategic partnerships,
regulatory pathways, scalable manufacturing practices that ensure clinical efficacy and safety,
and an examination of successful funding mechanisms. Attendees will gain valuable knowledge
around navigating the complexities of translational medicine, and will learn how to effectively
translate cutting-edge research into life-changing therapies, driving innovation and improving
patient outcomes.
 
16:00 – 16:05

Opening Remarks

Huey-Kang Sytwu, President, National Health Research Institutes; Distinguished Investigator, National Institute of Infectious Diseases and Vaccinology, NHRI; Academician, Academia Sinica

16:05 – 16:25

Understanding Protein Dynamics for Structure-based Drug Design: Design Stories of Crizotinib, Lorlatinib and Repotrectinib

Jingrong Jean Cui, President & CEO, BlossomHill Therapeutics, Inc.
16:25 – 16:45

Bozitinib: from Bench to Bedside

Boyu Zhong,President, CSO, Tyligand Bioscience Ltd.
16:45 – 17:05

Translation Medicine from CMC perspectives, from Preclinical to Commercial

David Chang, Ph.D., CEO, Taiwan Bio-Manufacturing Corporation (TBMC)
17:05 – 17:30

Panel Discussion

Moderator:
Hsing-Pang Hsieh, Director, National Health Research Institutes, Institute of Biotechnology and Pharmaceutical Research (IBPR)

Panelists:

09:00 – 10:30

Session 11 – AI for Pharma

With the explosive update of generative artificial intelligence (AI) tools such as ChatGPT across
multiple business domains, AI is one topic you can't afford to ignore. Here we'll explore the
transformative role of AI in the pharmaceutical industry, with a spotlight on its uptake in Asia.
We'll highlight AI's impact on drug discovery and development, showcasing how it can
successfully identify drug candidates, optimize clinical trial designs, and predict drug
interactions. Case studies will demonstrate successful AI integration in the pharmaceutical
industry, and how it's currently driving both innovation and efficiency. Attendees will gain
insights into leveraging AI tools to streamline development pipelines and enhance therapeutic
outcomes. AI is reshaping the pharmaceutical landscape in Asia; be sure to join us to find out
how.
09:00 – 09:05

Opening Remarks

09:05 – 09:20

Improving AI Analytical and Predictive Power in Drug Discovery Through Deep Learning Methodologies and Industry Collaboration

Tom Diethe, Head of The Centre for Artificial Intelligence, AstraZeneca, Cambridge UK
09:20 – 09:35

Unlocking the Potential of AI for High-Throughput Immunotherapy Drug Discovery Through RNA Splicing

Martin Akerman, Co-Founder & CTO, Envisagenics
09:35 – 09:45

Enhancing Drug Discovery with Nuclear Magnetic Resonance & Artificial Intelligence

Thomas Evangelidis, Founder, CEO & CTO, AI|ffinity s.r.o.

09:45 – 09:55

Integrating Artificial Intelligence in the Design and Discovery of Novel Protein Degraders

Shu-Jen Chen, Chief Scientific Officer, AnHorn Medicines Co., Ltd.

09:55 – 10:10

Enable Smart, Data-driven Decisions Through AI in Clinical Development Programs

NaHyun Kim, Ph.D., Solution Sales Specialist, Medidata AI, Dassault Systèmes, Medidata

10:10 – 10:30

Panel Discussion

Moderator:
Ching-Yung Lin, CEO,  Graphen, Inc. (Inviting)

Panelists:

10:45 – 12:15

Session 12– Advances in Genetics and Precision Medicine in Human Diseases

Precision medicine is a discipline that continues to evolve. In this session we'll examine the
latest advancements and applications in this field from a distinguished panel of experts within
both precision medicine and precision health domains. We'll discover how genomic profiling and
personalized treatment strategies are revolutionizing breast cancer care, making a real
difference to patient outcomes. Additionally, we'll highlight breakthroughs in precision
respiratory medicine, such as individualized plans for asthma and chronic obstructive pulmonary
disease (COPD), leveraging genetic and biomarker data. Attendees will gain insights into the
latest research, clinical practices, and future directions in precision medicine and in the wider-
scoped field of precision health. Please join us to learn how precision medicine is transforming
healthcare by providing more personalized and effective treatments.
10:45 – 10:50

Opening Remarks

Kang-Yun Lee, Executive Vice President, Taipei Medical University

10:50 – 11:10

Development of Peptide-Based PPI Inhibitor Targeting the BIG3-PHB2 cancer specific complex for Breast Cancer

Toyomasa Katagiri, Director, National Institutes of Biomedical Innovation, Health and Nutrition

11:10 – 11:30
 

Bioinformatics in Precision Medicine. (TBC)

Chunhua WENG., PhD, FACMI, FIAHSI.  Professor of Biomedical Informatics at Columbia University

11:30 – 11:50

Development of Precision Respiratory Medicine for chronic inflammation and infection

Kazuhiro/Ito, Professor, Imperial College London

11:50 – 12:15

Panel Discussion

Moderator:

Panelists:

12:25 – 13:55

Session 13 – Shaping the Future of Digital Health

As more and more elements of healthcare are encompassed into the ever-growing domain of
digital health, join us over lunch as we delve into the latest trends and business strategies in this
field. We'll examine key trends such as telemedicine, wearable health tech, AI-driven
diagnostics, and personalized health apps. In breaking down digital health's transformative
impact on healthcare delivery, this session will also showcase successful global business
strategies and the companies that are navigating the digital health landscape to drive innovation
and market growth. Our lineup of local and international digital health experts will offer their
insights on how to bridge and expand the cross-disciplinary digital health community.
12:25 - 12:35

Opening Remarks

  • Representative from MOEA, Taiwan
  • Eric Y. Chuang, General Director, Biomedical Technology and Device Research Laboratories (BDL), ITRI
12:35 - 13:15

Digital Health Trends and Global Business Strategies

  • Nipun Jain, Head of Innovation Hubs &Partnerships for International, AstraZeneca
  • Tony Lee, Field Sales Executive, Google Cloud
13:15 - 13:55

Panel Discussion: Bridging the Gap – Expand the Cross-Disciplinary Digital Health Community

Moderator:
Eric Y. Chuang, General Director, BDL, ITRI

Panelists:

  • Nipun Jain, Head of Innovation Hubs & Partnerships for International Region, AstraZeneca
  • Tony Lee, Field Sales Executive, Google Cloud
  • Kai-Cheng Hsu, Chief Medical Officer and Division Director, Biomedical Big Data & Artificial Intelligence Technology Division, BDL, ITRI
  • Peter Kurz, Chief Strategy Officer, Quantum International Corp. (QIC)
  • Jing-Wei Lee, Superintendent, National Cheng Kung University Hospital (NCKUH)